- $5.95bn
- $10.77bn
- $5.10bn
Contact lens maker Bausch + Lomb rules out take-private deal
RBC ups Ray-Ban maker EssilorLuxottica on promising growth in ophthalmology
Brief: Bausch + Lomb Bolsters Pipeline With Acquisition Of Whitecap Biosciences
Brief: Inflammx Therapeutics Announces Option Agreement With Bausch + Lomb
Bausch + Lomb buyout gets blurry beyond $7 bln
Brief: Bausch + Lomb Responds To Rumors Of A Potential Sale
Contact lens maker Bausch + Lomb confirms it is exploring sale (updated)
Contact lens maker Bausch + Lomb confirms it is exploring sale
Brief: Blackstone Has Cooled On Taking Part In Joint Takeover Bid For Eyecare Company Bausch + Lomb - FT
Brief: Bausch + Lomb borrows $400 million in new term loans
Brief: Banks, Private Credit Firms Compete To Provide $5 Bln Financing For Bausch + Lomb Takeover, Takeover Could Value Co At $10 Bln - Bloomberg News
Press Digest: Financial Times - Oct 15
U.S. STOCKS ON THE MOVE-Bausch + Lomb, SpartanNash, Hologic
Bausch + Lomb rises on FDA approval of lenses for cataract surgery
Brief: Bausch + Lomb Receives FDA Approval For Envista Envy Full Range Of Vision Intraocular Lens
Brief: TPG and Blackstone Team Up To Bid For Eyecare Company Bausch + Lomb - FT
Brief: Blackstone, Advent International And TPG Capital Are Among A Long List Of Private Equity Firms Studying Bids For Bausch + Lomb- FT
Bausch + Lomb gains after report co exploring sale
Brief: Eyecare Company Bausch + Lomb Explores Sale To End Messy Spin-Off- Ft